AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12638645
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for tobacco dependence in alcoholic smokers
Trial: 12638645
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy and 12-step approaches
Trial: 12638645
Drug: Further research
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Further research on effective treatments
Trial: 10798820
Drug: Lamotrigine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (25 mg once daily for 1 week, 50 mg once daily for the second week, and 100 mg once daily for the last 2 weeks)
Trial: 10798820
Drug: Lithium (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (400 mg twice daily)
Trial: 7625346
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (SL; 300 micrograms/d, n = 14)
Trial: 2522902
Drug: Long-acting GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting GnRH agonist (3.2 mg intramuscularly)
Trial: 2522902
Drug: Combined GnRH-agonist/gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined GnRH-agonist/gonadotropin stimulation
Trial: 331057
Drug: Kavain (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kavain (200 mg per capsule, 2 capsules per day)
Trial: 20197485
Drug: CS-8958 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8958 (20 mg inhaled dose)
Trial: 19811351
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LOS + 25 mg HCTZ (test formulation)
Trial: 19811351
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Hyzaar)
Trial: 16762012
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (TA) injection (0.5 ml at 40 mg/ml)
Trial: 14770445
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa fixed dose (325 microg)
Trial: 14770445
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa weight-based dose (4.5 microg/kg)
Trial: 11423594
Drug: Active TENS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TENS plus standard medication
Trial: 11423594
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication only (midazolam)
Trial: 11423594
Drug: Non‐functioning TENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐functioning TENS and standard medication
Trial: 25494967
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 2000 or 500 mg
Trial: 25494967
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (ivMP) 7.5 g
Trial: 22018131
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel)
Trial: 22018131
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal rings (daily release of 15 mcg ethinyl estradiol/120 mcg etonogestrel)
Trial: 10787361
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 1380)
Trial: 1485178
Drug: Ondansetron 1
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 1 mg, 4 mg, or 8 mg, three times per day for 3 days
Trial: 1485178
Drug: Ondansetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (all doses)
Trial: 6729868
Drug: Pendulum therapy
RxNorm normalized name: Aconitum pendulum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pendulum therapy (2000 cGy in ten fractions)
Trial: 6729868
Drug: Stationary field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stationary field therapy (2000 cGy in ten fractions)
Trial: 30367673
Drug: Sucrose vaginal
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose vaginal gel
Trial: 24346164
Drug: Multilevel models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilevel models with varying individual-level variances and correlations across treatment arms
Trial: 24346164
Drug: Multilevel models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilevel models with fixed individual-level variances and correlations across treatment arms
Trial: 18435426
Drug: Lung-volume-reduction surgery
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-volume-reduction surgery plus medical therapy
Trial: 11419683
Drug: Mebendazole 200
RxNorm normalized name: mebendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 200 mg thrice daily for 5 days
Trial: 11419683
Drug: Metronidazole 15
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 15 mg/kg/day in three divided doses for 7 days
Trial: 9268175
Drug: Dalteparin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (low molecular weight heparin), given subcutaneously once daily
Trial: 9268175
Drug: Unfractionated heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin, continuous intravenous infusion
Trial: 8111817
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core 30 mg/day
Trial: 8111817
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core 60 mg/day
Trial: 8111817
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core 90 mg/day
Trial: 8111817
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core (all doses)
Trial: 3103730
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg aminohydroxypropylidene diphosphonate
Trial: 934677
Drug: New variants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New variants of the Pinkel treatment scheme
Trial: 27259298
Drug: Hypoglycemic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic and antihypertensive drug use
Trial: 20679904
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ilaprazole
Trial: 20679904
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ilaprazole
Trial: 20679904
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ilaprazole
Trial: 16834791
Drug: Meptazinol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (2.5 mg kg‐1)
Trial: 15704320
Drug: LifeSite Hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LifeSite Hemodialysis System with 70% isopropyl alcohol as the antimicrobial solution
Trial: 11697835
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period)
Trial: 11697835
Drug: Intravenous CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) administered every three weeks
Trial: 9208260
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 treatment
Trial: 9208260
Drug: Normal controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal controls (before treatment)
Trial: 30305092
Drug: Otic gel
RxNorm normalized name: Otic Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otic gel containing 1% florfenicol, 1% terbinafine and 0.1% betamethasone acetate applied twice with a one‐week interval
Trial: 30305092
Drug: Suspension containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension containing hydrocortisone aceponate, miconazole and gentamicin administered daily for 5 days
Trial: 30305092
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (otic gel and suspension)
Trial: 8345370
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with 30 micrograms/kg intravenous (i.v.) alfentanil, 2.5 mg/kg i.v. thiopental, and 0.1 mg/kg i.v. vecuronium, maintained with 0.5 microgram/kg/min alfentanil, nitrous oxide (N2O) 67% in oxygen, and 0.8 microgram/kg/min vecuronium.
Trial: 8345370
Drug: Adjunctive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapy with one of three different treatment modalities (20 to 60 micrograms/kg i.v. alfentanil, 0.5 to 2.0% inspired isoflurane, or 0.05 to 0.15 mg/kg i.v. trimethaphan).
Trial: 3946979
Drug: Dialysate Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate Ca concentration of 7.5 mg/dL
Trial: 3946979
Drug: Dialysate Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate Ca concentration of 5.5 mg/dL
Trial: 25330687
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg-norgestimate 250 mcg-ethinyl estradiol 35 microg (Group A)
Trial: 25330687
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 12 mg-ethinyl estradiol 35 microg (Group B)
Trial: 25330687
Drug: Norgestimate 250
RxNorm normalized name: ethinyl estradiol 25 MCG / norgestimate 250 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate 250 mcg-ethinyl estradiol 35 microg (Group C)
Trial: 23031562
Drug: LND +
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LND + RE (low energy, low CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Trial: 23031562
Drug: HND +
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HND + RE (high energy, high CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Trial: 18338628
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) theory
Trial: 6388916
Drug: Budesonide (freon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (freon propellant device - Rhinocort) 400 micrograms daily
Trial: 6388916
Drug: Budesonide (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (water solution in mechanical pump spray) 400 micrograms daily
Trial: 6388916
Drug: Budesonide (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (water solution in mechanical pump spray) 200 micrograms daily
Trial: 28961958
Drug: Online life
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online life review therapy with online counseling
Trial: 28961958
Drug: Online life
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online life review therapy with online peer support
Trial: 17537772
Drug: Beta-lactam macrolide
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam macrolide combination therapy
Trial: 17537772
Drug: Beta-lactam alone
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam alone monotherapy
Trial: 17537772
Drug: Matched groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched groups (27 patients each from monotherapy and combination therapy)
Trial: 10068095
Drug: Interferon monotherapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon monotherapy (6 months)
Trial: 10068095
Drug: Interferon monotherapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon monotherapy (up to 12 months)
Trial: 10068095
Drug: Interferon-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin combination therapy (6 months)
Trial: 8830203
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 2 hours after surgery (Trial 1)
Trial: 8830203
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 3 hours after surgery (Trial 2)
Trial: 8830203
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (50 mg)
Trial: 6775298
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NGS) 0.75 mg
Trial: 6775298
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (NGO) 15 mg
Trial: 26823335
Drug: HRV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV administered at 6 and 10 weeks (group 1)
Trial: 26823335
Drug: HRV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV administered at 10 and 14 weeks (group 2)
Trial: 26823335
Drug: HRV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV administered at 6, 10, and 14 weeks (group 3)
Trial: 22781186
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg capsules of ginger root powder, three times a day)
Trial: 22781186
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsules, three times a day)
Trial: 19038375
Drug: 350‐mm(2) Baerveldt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350‐mm(2) Baerveldt glaucoma implant (tube group)
Trial: 11926711
Drug: Non-invasive ventilation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive ventilation (NIV) plus standard medical therapy (ST)
Trial: 11926711
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (ST) alone
Trial: 8088297
Drug: anti-regurgitation formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-regurgitation formula with thickening product, positional treatment, parental reassurance
Trial: 8088297
Drug: placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (same formula without thickening product, positional treatment, parental reassurance)
Trial: 2764265
Drug: Pentaglobin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaglobin (10 g daily on the 3rd, 4th, and 5th day)
Trial: 2764265
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin (12.5 g daily on the 3rd, 4th, and 5th day)
Trial: 27606566
Drug: Enamelon® Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamelon® Preventive Treatment Gel (EPTG) with 0.4% stannous fluoride
Trial: 27606566
Drug: Biotene® Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene® Oral Balance Gel (BOBG)
Trial: 25608984
Drug: Topical leek
RxNorm normalized name: Leek
DrugBank: Leek (DB10659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical leek extract cream
Trial: 25608984
Drug: Standard antihemorrhoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antihemorrhoid cream
Trial: 22940055
Drug: 75 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 cGy 131-Iodine tositumomab with high-dose BEAM (carmustine, etoposide, cytarabine, and melphalan) followed by autologous stem cell transplantation
Trial: 16818865
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment by experts
Trial: 7531022
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus transcatheter hepatic artery infusion chemotherapy (TAI) and embolisation (IAE) treatment (Group B)
Trial: 7531022
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus systemic chemotherapy (Group C)
Trial: 3278764
Drug: O-(beta-hydroxyethyl)-rutosides (oxerutin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-(beta-hydroxyethyl)-rutosides (oxerutin; 'Paroven', 'Venoruton', Zyma) 3 g/day
Trial: 30975645
Drug: Steroid (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (methylprednisolone 40 mg)
Trial: 28480412
Drug: liver‐softening medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liver‐softening medicine plus glucosamine
Trial: 23993865
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of maintenance medication
Trial: 23993865
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of medication
Trial: 29117091
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both expert and novice demonstrations
Trial: 16783669
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (Group K: n=22)
Trial: 16783669
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Group S: n=23)
Trial: 7696447
Drug: Budesonide enema,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema, 2 mg/100 mL (Entocort)
Trial: 7696447
Drug: Hydrocortisone acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone acetate foam enema, 125 mg (Colifoam)
Trial: 2431838
Drug: Theophylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (600 mg daily)
Trial: 2431838
Drug: Enprofylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (600 mg daily)
Trial: 28732741
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert saline solution)
Trial: 26710954
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml oral lactulose solution, twice a day for 4 weeks
Trial: 2872809
Drug: Terazosin (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (once daily)
Trial: 2872809
Drug: Prazosin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (twice daily)
Trial: 28176470
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg (fasted) under unmodified gastric pH
Trial: 28176470
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg (fasted) 1 hour after ranitidine 450 mg (elevated gastric pH)
Trial: 24479279
Drug: G‐aenial Flo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐aenial Flo bulk fill (GF)
Trial: 24479279
Drug: G‐aenial Universal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐aenial Universal Flo bulk fill (GUF)
Trial: 20825806
Drug: Placebo lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lubricant gel
Trial: 16388507
Drug: Group-1 (PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-1 (PSA cut-off of 4.0 ng/ml and/or abnormal DRE/TRUS)
Trial: 16388507
Drug: Group-2 (PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-2 (PSA cut-off of 3.0 ng/ml)